KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbbVie (ABBV) Return on Equity (2016 - 2025)

AbbVie (ABBV) has disclosed Return on Equity for 13 consecutive years, with 1.76% as the latest value for Q1 2025.

  • On a quarterly basis, Return on Equity rose 107.0% to 1.76% in Q1 2025 year-over-year; TTM through Mar 2025 was 1.76%, a 107.0% increase, with the full-year FY2024 number at 0.62%, up 27.0% from a year prior.
  • Return on Equity was 1.76% for Q1 2025 at AbbVie, up from 0.91% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 1.76% in Q1 2025 to a low of 0.39% in Q1 2021.
  • A 5-year average of 0.73% and a median of 0.71% in 2022 define the central range for Return on Equity.
  • Biggest YoY gain for Return on Equity was 147bps in 2021; the steepest drop was -139bps in 2021.
  • AbbVie's Return on Equity stood at 0.8% in 2021, then fell by -11bps to 0.71% in 2022, then plummeted by -39bps to 0.43% in 2023, then skyrocketed by 111bps to 0.91% in 2024, then skyrocketed by 92bps to 1.76% in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Return on Equity are 1.76% (Q1 2025), 0.91% (Q4 2024), and 0.85% (Q3 2024).